{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:54:47Z","timestamp":1787313287678,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00508-024-02365-x","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T07:01:47Z","timestamp":1715670107000},"page":"297-306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["25\u00a0years of lipid-lowering therapy: secular trends in therapy of coronary patients"],"prefix":"10.1007","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8962-0749","authenticated-orcid":false,"given":"Magdalena","family":"Ratz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5443-860X","authenticated-orcid":false,"given":"Johannes B.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"K\u00fchrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph H.","family":"S\u00e4ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"M\u00fcndlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Vonbank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Mader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fraunberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3776-5704","authenticated-orcid":false,"given":"Andreas","family":"Leiherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"issue":"290","key":"2365_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"2019","author":"F Mach","year":"2019","unstructured":"Mach\u00a0F, Baigent\u00a0C, Catapano\u00a0AL, et\u00a0al. ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;2019(290):140\u2013205.","journal-title":"Atherosclerosis"},{"key":"2365_CR2","first-page":"77","volume":"1","author":"European Atherosclerosis Society","year":"1987","unstructured":"European Atherosclerosis Society. Strategies for the prevention of coronary heart disease: a\u00a0policy statement of the European Atherosclerosis Society. Eur Heart\u00a0J. 1987;1:77\u201388.","journal-title":"Eur Heart J"},{"key":"2365_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0021-9150(94)90200-3","volume":"110","author":"K Py\u00f6r\u00e4l\u00e4","year":"1994","unstructured":"Py\u00f6r\u00e4l\u00e4\u00a0K, De Backer\u00a0G, Graham\u00a0I, Poole-Wilson\u00a0P, Wood\u00a0D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis. 1994;110:121\u201361.","journal-title":"Atherosclerosis"},{"key":"2365_CR4","first-page":"1383","volume":"344","author":"Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383\u20139.","journal-title":"Lancet"},{"issue":"1","key":"2365_CR5","first-page":"CD004816","volume":"2013","author":"F Taylor","year":"2013","unstructured":"Taylor F, Huffman MD, Macedo AF et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013; 2013(1):CD004816.","journal-title":"Cochrane Database Syst Rev"},{"key":"2365_CR6","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1007\/s12325-021-01892-7","volume":"38","author":"F Rea","year":"2021","unstructured":"Rea\u00a0F, Savar\u00e9\u00a0L, Corrao\u00a0G, Mancia\u00a0G. Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe. Adv Ther. 2021;38:5270\u201385.","journal-title":"Adv Ther"},{"key":"2365_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","volume":"325","author":"M Averna","year":"2021","unstructured":"Averna\u00a0M, Banach\u00a0M, Bruckert\u00a0E et\u00a0al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A\u00a0statement from a\u00a0European Atherosclerosis Society Task Force. Atherosclerosis. 2021;325:99\u2013109.","journal-title":"Atherosclerosis"},{"key":"2365_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","volume":"11","author":"KK Ray","year":"2023","unstructured":"Ray\u00a0KK, Troquay\u00a0RPT, Visseren\u00a0FLJ et\u00a0al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4\u2011year open-label extension of the ORION-1\u00a0trial. Lancet Diabetes Endocrinol. 2023;11:109\u201319.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"39","key":"2365_CR9","first-page":"1131","volume":"2018","author":"U Landmesser","year":"2017","unstructured":"Landmesser\u00a0U, Chapman\u00a0MJ, Stock\u00a0JK, et\u00a0al. Update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type\u00a09 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart\u00a0J. 2017;2018(39):1131\u201343.","journal-title":"Eur Heart J"},{"issue":"7","key":"2365_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ, et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019;8(7):e011662.","journal-title":"J Am Heart Assoc"},{"key":"2365_CR11","doi-asserted-by":"crossref","unstructured":"Goldberg AC, Leiter LA, Stroes ESG et\u00a0al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA 2019; 322: 1780\u20131788.","DOI":"10.1001\/jama.2019.16585"},{"key":"2365_CR12","doi-asserted-by":"publisher","first-page":"e024937","DOI":"10.1136\/bmjopen-2018-024937","volume":"9","author":"Y Wang","year":"2019","unstructured":"Wang\u00a0Y, Nichol\u00a0MB, Yan\u00a0BPY, Wu\u00a0J, Tomlinson\u00a0B, Lee\u00a0VWY. Descriptive analysis of real-world medication use pattern of statins and antiplatelet agents among patients with acute coronary syndrome in Hong Kong and the USA. Bmj Open. 2019;9:e24937.","journal-title":"Bmj Open"},{"key":"2365_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00392-020-01740-8","volume":"111","author":"JL Katzmann","year":"2022","unstructured":"Katzmann\u00a0JL, Sorio-Vilela\u00a0F, Dornstauder\u00a0E et\u00a0al. Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin\/ezetimibe compared to separate pill combination on LDL\u2011C. Clin Res Cardiol. 2022;111:243\u201352.","journal-title":"Clin Res Cardiol"},{"issue":"129","key":"2365_CR14","first-page":"1","volume":"2014","author":"NJ Stone","year":"2013","unstructured":"Stone\u00a0NJ, Robinson\u00a0JG, Lichtenstein\u00a0AH, et\u00a0al. ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A\u00a0report of the american college of cardiology\/american heart association task force on practice guidelines. Circulation. 2013;2014(129):1\u201345.","journal-title":"Circulation"},{"key":"2365_CR15","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1053\/euhj.1998.1243","volume":"19","author":"D Wood","year":"1998","unstructured":"Wood\u00a0D, De Backer\u00a0G, Faergeman\u00a0O, Graham\u00a0I, Mancia\u00a0G, Py\u00f6r\u00e4l\u00e4\u00a0K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart\u00a0J. 1998;19:1434\u2013503.","journal-title":"Eur Heart J"},{"key":"2365_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.atherosclerosis.2004.02.013","volume":"173","author":"G De Backer","year":"2004","unstructured":"De Backer\u00a0G, Ambrosioni\u00a0E, Borch-Johnsen\u00a0K et\u00a0al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Atherosclerosis. 2004;173:379\u201389.","journal-title":"Atherosclerosis"},{"key":"2365_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/j.1365-2796.2006.01730.x","volume":"260","author":"M Eliasson","year":"2006","unstructured":"Eliasson\u00a0M, Janlert\u00a0U, Jansson\u00a0J\u2011H, Stegmayr\u00a0B. Time trends in population cholesterol levels 1986\u20132004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study. J\u00a0Intern Med. 2006;260:551\u20139.","journal-title":"J Intern Med"},{"key":"2365_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1161\/01.CIR.96.1.308","volume":"96","author":"SS Franklin","year":"1997","unstructured":"Franklin\u00a0SS, Gustin\u00a0IVW, Wong\u00a0ND et\u00a0al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96:308\u201315.","journal-title":"Circulation"},{"key":"2365_CR19","doi-asserted-by":"publisher","first-page":"109097","DOI":"10.1016\/j.isci.2024.109097","volume":"27","author":"A Leiherer","year":"2024","unstructured":"Leiherer\u00a0A, Brozek\u00a0W, Muendlein\u00a0A et\u00a0al. The value of earlier-in-life systolic and diastolic blood pressure for cardiovascular risk prediction. iScience. 2024;27:109097.","journal-title":"iScience"},{"key":"2365_CR20","doi-asserted-by":"publisher","first-page":"103371","DOI":"10.1016\/j.ebiom.2021.103371","volume":"67","author":"A Leiherer","year":"2021","unstructured":"Leiherer\u00a0A, Ulmer\u00a0H, Muendlein\u00a0A et\u00a0al. Value of total cholesterol readings earlier versus later in life to predict cardiovascular risk. EBioMedicine. 2021;67:103371.","journal-title":"EBioMedicine"},{"key":"2365_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.110.002774","volume":"125","author":"N Allen","year":"2012","unstructured":"Allen\u00a0N, Berry\u00a0JD, Ning\u00a0H, Van Horn\u00a0L, Dyer\u00a0A, Lloyd-Jones\u00a0DM. Impact of Blood Pressure and Blood Pressure Change during Middle Age on the Remaining Lifetime Risk for Cardiovascular Disease: The Cardiovascular Lifetime Risk Pooling Project. Circulation. 2012;125:37.","journal-title":"Circulation"},{"key":"2365_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/ije\/dyv031","volume":"44","author":"I Postmus","year":"2015","unstructured":"Postmus\u00a0I, Deelen\u00a0J, Sedaghat\u00a0S et\u00a0al. LDL cholesterol still a\u00a0problem in old age? A\u00a0Mendelian randomization study. Int J Epidemiol. 2015;44:604\u201312.","journal-title":"Int J Epidemiol"},{"issue":"6","key":"2365_CR23","doi-asserted-by":"publisher","first-page":"oeac070","DOI":"10.1093\/ehjopen\/oeac070","volume":"2","author":"I Engebretsen","year":"2022","unstructured":"Engebretsen\u00a0I, Munkhaugen J, Bugge C et al. Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs. Eur Heart J Open. 2022;2(6):oeac070.","journal-title":"Eur Heart J Open"},{"key":"2365_CR24","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray\u00a0KK, Molemans\u00a0B, Schoonen\u00a0MW et\u00a0al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021;28:1279\u201389.","journal-title":"Eur J Prev Cardiol"},{"key":"2365_CR25","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s00508-021-01978-w","volume":"134","author":"P Siostrzonek","year":"2022","unstructured":"Siostrzonek\u00a0P, Brath\u00a0H, Zweiker\u00a0R et\u00a0al. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL\u2011C goals achieved?: Results from the DA VINCI study. Wien Klin Wochenschr. 2022;134:294\u2013301.","journal-title":"Wien Klin Wochenschr"},{"key":"2365_CR26","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1177\/2047487318825350","volume":"26","author":"K Kotseva","year":"2019","unstructured":"Kotseva\u00a0K, De Backer\u00a0G, De Bacquer\u00a0D et\u00a0al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27\u00a0countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26:824\u201335.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"2365_CR27","doi-asserted-by":"publisher","first-page":"oeac071","DOI":"10.1093\/ehjopen\/oeac071","volume":"2","author":"M Banach","year":"2022","unstructured":"Banach M, Penson PE. Adherence to statin therapy: it seems we know everything, yet we do nothing. Eur Heart J Open. 2022;2(6):oeac071.","journal-title":"Eur Heart J Open"},{"key":"2365_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","volume":"285","author":"G De Backer","year":"2019","unstructured":"De Backer\u00a0G, Jankowski\u00a0P, Kotseva\u00a0K et\u00a0al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27\u00a0countries. Atherosclerosis. 2019;285:135\u201346.","journal-title":"Atherosclerosis"},{"issue":"253","key":"2365_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"2016","author":"AL Catapano","year":"2016","unstructured":"Catapano\u00a0AL, Graham\u00a0I, De Backer\u00a0G, et\u00a0al. ESC\/EAS Guidelines for the Management of Dyslipidaemias. Atherosclerosis. 2016;2016(253):281\u2013344.","journal-title":"Atherosclerosis"},{"key":"2365_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14740338.2018.1394455","volume":"17","author":"S Bellosta","year":"2018","unstructured":"Bellosta\u00a0S, Corsini\u00a0A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018;17:25\u201337.","journal-title":"Expert Opin Drug Saf"},{"key":"2365_CR31","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","volume":"8","author":"KA Kellick","year":"2014","unstructured":"Kellick\u00a0KA, Bottorff\u00a0M, Toth\u00a0PP. A\u00a0clinician\u2019s guide to statin drug-drug interactions. J\u00a0Clin Lipidol. 2014;8:S30\u2013S46.","journal-title":"J Clin Lipidol"},{"key":"2365_CR32","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00508-023-02296-z","volume":"135","author":"AL Burger","year":"2023","unstructured":"Burger\u00a0AL, Beran\u00a0N, Pogran\u00a0E et\u00a0al. Low-density lipoprotein cholesterol reduction with immediate combination therapy of statin and ezetimibe compared to statin monotherapy after percutaneous coronary intervention. Wien Klin Wochenschr. 2023;135:674\u20139.","journal-title":"Wien Klin Wochenschr"},{"key":"2365_CR33","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine\u00a0MS, Giugliano\u00a0RP, Keech\u00a0AC et\u00a0al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N\u00a0Engl J Med. 2017;376:1713\u201322.","journal-title":"Disease. N\u00a0Engl J Med"},{"key":"2365_CR34","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz\u00a0GG, Steg\u00a0PG, Szarek\u00a0M et\u00a0al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N\u00a0Engl J Med. 2018;379:2097\u2013107.","journal-title":"Syndrome. N\u00a0Engl J Med"},{"key":"2365_CR35","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.amepre.2022.10.010","volume":"64","author":"A Sekkarie","year":"2023","unstructured":"Sekkarie\u00a0A, Park\u00a0S, Therrien\u00a0NL et\u00a0al. Trends in Lipid-Lowering Prescriptions: Increasing Use of Guideline-Concordant Pharmacotherapies, U.S. Am J Prev Med. 2023;64:561\u2013566.","journal-title":"Am J Prev Med"},{"key":"2365_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/ehjcvp\/pvac072","volume":"9","author":"H Drexel","year":"2023","unstructured":"Drexel\u00a0H, Saely\u00a0CH, Fibrates\u00a0AS. One more lost paradise in lipid treatment. Eur Heart J Cardiovasc Pharmacother. 2023;9:121.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"6","key":"2365_CR37","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/ehjcvp\/pvad044","volume":"9","author":"H Drexel","year":"2023","unstructured":"Drexel H, Tamargo J, Kaski JC et al. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease? Eur Heart J Cardiovasc Pharmacother. 2023;9(6):570\u2013582.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"12","key":"2365_CR38","doi-asserted-by":"publisher","first-page":"e0259467","DOI":"10.1371\/journal.pone.0259467","volume":"16","author":"Y Lee","year":"2021","unstructured":"Lee Y, Shin J, Kim Y, Kim DS. Consumption of single products versus fixed-dose combination medicines for hypertension and hyperlipidemia during 2015\u20132019 in South Korea. PLoS ONE. 2021;16(12):e0259467.","journal-title":"PLoS ONE"},{"key":"2365_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2017.05.018","volume":"263","author":"V Guglielmi","year":"2017","unstructured":"Guglielmi\u00a0V, Bellia\u00a0A, Pecchioli\u00a0S et\u00a0al. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A\u00a0real-world evidence study in primary care. Atherosclerosis. 2017;263:36\u201341.","journal-title":"Atherosclerosis"},{"issue":"41","key":"2365_CR40","first-page":"407","volume":"2020","author":"FJ Neumann","year":"2019","unstructured":"Neumann\u00a0FJ, Sechtem\u00a0U, Banning\u00a0AP, et\u00a0al. ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart\u00a0J. 2019;2020(41):407\u201377.","journal-title":"Eur Heart J"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02365-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-024-02365-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02365-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T01:55:48Z","timestamp":1747274148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-024-02365-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":40,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2365"],"URL":"https:\/\/doi.org\/10.1007\/s00508-024-02365-x","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"20 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Ratz, J.B.\u00a0Vogel, H.\u00a0K\u00fchrer, C.H.\u00a0S\u00e4ly, A.\u00a0M\u00fcndlein, A.\u00a0Vonbank, A.\u00a0Mader, P.\u00a0Fraunberger, A.\u00a0Leiherer and H.\u00a0Drexel declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}